dangers of taking glp-1 Drugs and Eating Disorders: A Hidden Risk in the Weight Loss Revolution – The Chicago Council on Science and Technology Quoted in the The Wall

Oral GLP-1s: Orforglipron (Eli Lilly's oral medication) showed 7.8-12.4% weight loss in phase 3 trials

These medications, particularly Glucagon-Like Peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide, have been clinically validated to treat both conditions, triggering metabolic cascades that significantly improve disease outcomes

The time to reach maintenance dose varies by medication, typically ranging from 4 weeks for some formulations to 1620 weeks for others such as semaglutide (Wegovy)

Elan Simckes, we combine advanced reproductive technologies with compassionate, patient-centered guidance